Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DXd plus Pyrotinib in Advanced HER2-positive Breast Cancer Progressed After T-DXd
NCT07836257Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pyrotinib in breast cancer, sponsored by Fujian Medical University. Primary endpoint: Objective Response Rate at 3 years. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07836257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07836257.